Nancy Gordon, MD
Allergy & Immunology · Philadelphia, PANPI 1679621734
Payments from drug & device makers
Across 420 payments — averaging $15.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$715
- Kaleo, Inc.$551
- CSL Behring$524
- Takeda Pharmaceuticals U.S.A., Inc.$388
- plus $2K from 21 others
What the payments were for
- Food & beverage$6,470100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 84 | $1,348 |
| GSK | 81 | $1,123 |
| Regeneron Healthcare Solutions, Inc. | 56 | $715 |
| Kaleo, Inc. | 34 | $551 |
| CSL Behring | 35 | $524 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $388 |
| Novartis | 22 | $305 |
| Sanofi | 13 | $218 |
| Optinose US, Inc. | 10 | $187 |
| Amgen | 9 | $151 |
| Hikma Pharmaceuticals USA | 8 | $115 |
| Biocryst US Sales Co., LLC | 5 | $108 |
| Boehringer Ingelheim | 5 | $104 |
| Genentech USA, Inc. | 5 | $91 |
| Pfizer | 6 | $84 |
| Shire North American Group Inc | 5 | $83 |
| Teva Pharmaceuticals USA, Inc. | 6 | $78 |
| Merck | 4 | $57 |
| Blueprint Medicines Corporation | 2 | $47 |
| Bio Products Laboratory USA, Inc. | 3 | $38 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $30 |
| Eyevance Pharmaceuticals LLC | 2 | $27 |
| Paratek Pharmaceuticals, Inc. | 1 | $25 |
| Octapharma USA, Inc. | 1 | $23 |
| Pharming Healthcare, Inc. | 1 | $19 |
| AbbVie | 1 | $14 |
| Alk-abello, Inc | 1 | $14 |
How this compares
$6,470 in reported general payments places this provider in the 60th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $91,701 |
| Breo ElliptaFluticasone/Vilanterol | 75 | $47,139 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 146 | $32,629 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $26,923 |
| Spiriva RespimatTiotropium Bromide | 23 | $24,482 |
| Advair HfaFluticasone Propion/Salmeterol | 38 | $23,830 |
| Arnuity ElliptaFluticasone Furoate | 48 | $16,196 |
| Wixela InhubFluticasone Propion/Salmeterol | 59 | $10,502 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 34 | $8,670 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,204 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,950 |
| Azelastine Hcl | 149 | $7,178 |
| Qvar RedihalerBeclomethasone Dipropionate | 13 | $6,605 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 22 | $6,300 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 157 | $5,632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $524 | $91,70114 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $1,123 | $90,259152 claims |
| Boehringer IngelheimSpiriva Respimat | $104 | $24,48223 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,348 | $16,15435 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $78 | $6,60513 claims |
| Hikma Pharmaceuticals USAEpinephrine | $115 | $4,40224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 175 allergy & immunology providers in Pennsylvania.
Other allergy & immunology in Philadelphia
- Drew WeissmanPhiladelphia$15.3M
- Rahul DattaPhiladelphia$198K
- Arnold LevinsonPhiladelphia$95K
- John BossoPhiladelphia$86K
- Elias AklPhiladelphia$80K
- Neha SirohiPhiladelphia$62K
- Marc GoldsteinPhiladelphia$22K
- Raquel EmpedradPhiladelphia$21K
- Karin Flynn-RoddenPhiladelphia$15K
- Donald DvorinPhiladelphia$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.